Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology leader focused on developing therapies for rare, autoimmune, and severe inflammatory diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, research breakthroughs, and strategic corporate initiatives shaping the company's trajectory.
Access authoritative information on Horizon's innovative treatments like TEPEZZA® and KRYSTEXXA®, along with analysis of key developments including partnership announcements and regulatory filings. Our curated news collection serves as your primary resource for understanding Horizon's position in the biopharmaceutical landscape and its commitment to addressing unmet medical needs.
Key updates cover clinical trial progress, FDA communications, financial results, and major corporate events such as Horizon's pending acquisition by Amgen following FTC clearance. All content is sourced from official releases and verified channels to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Horizon Therapeutics' evolving story. For additional context on the company's mission and pipeline, visit their official website at HorizonTherapeutics.com.
Horizon Therapeutics has shared promising data from the PROTECT trial, supporting KRYSTEXXA (pegloticase injection) for treating uncontrolled gout in kidney transplant patients. Presented at the ASN Kidney Week 2020, the trial indicates that patients receiving KRYSTEXXA showed significant reductions in serum uric acid levels. Among 15 enrolled patients, 5 completed treatment with sustained improvements, while 8 continued. The research highlights the drug's potential effectiveness without compromising kidney function, addressing a critical need among this vulnerable population.
Horizon Therapeutics plc (Nasdaq: HZNP) has announced new long-term data from its Phase 2 clinical trial of TEPEZZA (teprotumumab-trbw), showing sustained benefits in patients with Thyroid Eye Disease (TED) up to one year post-treatment. Key findings include that 97% of participants improved their clinical activity score and 70% achieved disease inactivation. TEPEZZA is the only FDA-approved treatment for TED, addressing a critical need for patients facing severe symptoms. These promising results support ongoing clinical evaluation and indicate the potential of TEPEZZA for long-term symptom relief.
Horizon Therapeutics plc (Nasdaq: HZNP) announced that new data on KRYSTEXXA (pegloticase injection) will be presented at the upcoming ACR Convergence conference from Nov. 5-9, 2020. This includes results from the RECIPE trial aimed at reducing immunogenicity of pegloticase in patients with uncontrolled gout. Presentations will focus on the impact of co-prescribing KRYSTEXXA with immunomodulators. Additionally, the company will host a discussion on Nov. 10 about these findings and their implications for treatment. Safety data indicate that the combination therapy's effectiveness remains unverified by health authorities.
Horizon Therapeutics plc (Nasdaq: HZNP) will announce its third-quarter 2020 financial results on November 2, 2020. A live webcast is scheduled for 8 a.m. Eastern Time to discuss the financial and operational performance. Interested parties can access the live stream and replay via the company's investor relations website.
Horizon focuses on developing medicines for rare and rheumatic diseases, aiming to provide clinically meaningful therapies through scientific expertise and compassion.
HemoShear Therapeutics has achieved a significant milestone in its collaboration with Horizon Therapeutics (NASDAQ: HZNP) for developing new gout therapies. The partnership, initiated in January 2019, has led to valuable insights and the receipt of an undisclosed milestone payment. The collaboration could yield over $500 million in potential milestone payments and royalties for HemoShear. Additionally, HemoShear has received FDA approval to start a Phase 2 study for its oral drug targeting methylmalonic acidemia and propionic acidemia.
